alendronate has been researched along with leuprolide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Horan, AH | 1 |
| Chin, JL; Kebabdjian, M; Klotz, LH; McNeill, IY; Zhang, L | 1 |
| Carles Galceran, J; Celma Domenech, A; Lorente Garcia, D; Morote Robles, J; Placer Santos, J; Planas Morin, J; Regis, L; Salvador Lacambra, C; Trilla Herrera, E | 1 |
1 trial(s) available for alendronate and leuprolide
| Article | Year |
|---|---|
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leupr
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers; Bone Density; Bone Density Conservation Agents; Canada; Chi-Square Distribution; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Hip Joint; Humans; Injections, Intramuscular; Leuprolide; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Patient Selection; Peptides; Predictive Value of Tests; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
3 other study(ies) available for alendronate and leuprolide
| Article | Year |
|---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Re: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer.
Topics: Aged; Alendronate; Animals; Antineoplastic Agents, Hormonal; Diphosphonates; Humans; Leuprolide; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Rats | 1996 |
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Anilides; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Femur Neck; Humans; Leuprolide; Lumbar Vertebrae; Male; Nitriles; Osteoporosis; Prostatic Neoplasms; Radiography; Tosyl Compounds | 2014 |